DE60107416D1 - Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion - Google Patents

Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Info

Publication number
DE60107416D1
DE60107416D1 DE60107416T DE60107416T DE60107416D1 DE 60107416 D1 DE60107416 D1 DE 60107416D1 DE 60107416 T DE60107416 T DE 60107416T DE 60107416 T DE60107416 T DE 60107416T DE 60107416 D1 DE60107416 D1 DE 60107416D1
Authority
DE
Germany
Prior art keywords
adnf
blends
memory function
improve learning
learning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60107416T
Other languages
English (en)
Other versions
DE60107416T2 (de
Inventor
Y Spong
Douglas Brenneman
Illana Gozes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
US Department of Health and Human Services
Original Assignee
Ramot at Tel Aviv University Ltd
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, US Department of Health and Human Services filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of DE60107416D1 publication Critical patent/DE60107416D1/de
Publication of DE60107416T2 publication Critical patent/DE60107416T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DE60107416T 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion Expired - Lifetime DE60107416T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20894400P 2000-05-31 2000-05-31
US208944P 2000-05-31
US26780501P 2001-02-08 2001-02-08
US267805P 2001-02-08
PCT/US2001/017758 WO2001092333A2 (en) 2000-05-31 2001-05-31 Use of adnf for enhancing learning and memory

Publications (2)

Publication Number Publication Date
DE60107416D1 true DE60107416D1 (de) 2004-12-30
DE60107416T2 DE60107416T2 (de) 2005-12-01

Family

ID=26903662

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60107416T Expired - Lifetime DE60107416T2 (de) 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Country Status (12)

Country Link
US (2) US7427598B2 (de)
EP (1) EP1285000B1 (de)
JP (1) JP4440536B2 (de)
CN (1) CN1444600A (de)
AT (1) ATE283286T1 (de)
AU (2) AU2001275111B2 (de)
CA (1) CA2410735A1 (de)
DE (1) DE60107416T2 (de)
HK (1) HK1054947A1 (de)
MX (1) MXPA02011923A (de)
NZ (1) NZ522821A (de)
WO (1) WO2001092333A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US7384908B1 (en) 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
WO2001092333A2 (en) * 2000-05-31 2001-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of adnf for enhancing learning and memory
AU2002335750A1 (en) * 2001-09-12 2003-03-24 Ramot At Tel-Aviv University Ltd. Neurotrophic components of the adnf i complex
JP5036302B2 (ja) * 2003-02-10 2012-09-26 ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ 炎症状態下に血液脳関門で示差的（ｄｉｆｆｅｒｅｎｔｉａｌｌｙ）に発現される核酸
WO2004080957A2 (en) 2003-03-12 2004-09-23 Ramot At Tel Aviv University Ltd. Use of adnf polypeptides for treating anxiety and depression
WO2005099741A1 (ja) 2004-04-08 2005-10-27 Noevir Co., Ltd. 運動ニューロン疾患治療薬
AU2006227528B2 (en) * 2005-03-23 2011-05-26 Allon Therapeutics, Inc. Use of ADNF polypeptides for treating peripheral neurotoxicity
TWI303567B (en) * 2005-12-20 2008-12-01 Ind Tech Res Inst Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
WO2007096859A2 (en) 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
JP2010536801A (ja) * 2007-08-24 2010-12-02 ラモト アト テルーアビブ ユニバーシティー リミテッド Ｎａｐ様ペプチド擬似体およびｓａｌ様ペプチド擬似体を用いた神経保護法
EP2467397A1 (de) 2009-08-17 2012-06-27 Ramot at Tel-Aviv University Ltd. Nap-alpha-aminoisobuttersäureanalogon mit nervenschützender wirkung
US9518994B2 (en) 2010-01-06 2016-12-13 Ramot At Tel Aviv University Method for diagnosing and monitoring schizophrenia and tauopathies
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
JP7201432B2 (ja) * 2015-11-18 2023-01-10 ヘランティス ファーマ ピーエルシー 中枢神経系疾患の鼻腔内治療に使用するためのｃｄｎｆまたはｍａｎｆを含む組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0662092B1 (de) 1991-04-22 2005-03-23 THE UNITED STATES OF AMERICA, represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aktivitätsabhängiger neurotropher faktor
US6174862B1 (en) * 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0639981A4 (de) * 1992-05-08 1995-06-28 Univ Jefferson Analoge des igf-faktors(18.01.94).
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
ATE266044T1 (de) 1999-08-18 2004-05-15 Univ Ramot Oral wirksame peptide, die zellschädigung und zelltod verhindern
WO2001092333A2 (en) * 2000-05-31 2001-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of adnf for enhancing learning and memory

Also Published As

Publication number Publication date
JP2003535105A (ja) 2003-11-25
CA2410735A1 (en) 2001-12-06
MXPA02011923A (es) 2004-09-06
DE60107416T2 (de) 2005-12-01
NZ522821A (en) 2004-08-27
EP1285000B1 (de) 2004-11-24
AU7511101A (en) 2001-12-11
CN1444600A (zh) 2003-09-24
WO2001092333A2 (en) 2001-12-06
JP4440536B2 (ja) 2010-03-24
WO2001092333A3 (en) 2002-05-30
AU2001275111B2 (en) 2006-07-06
HK1054947A1 (en) 2003-12-19
US20040048801A1 (en) 2004-03-11
US7427598B2 (en) 2008-09-23
ATE283286T1 (de) 2004-12-15
EP1285000A2 (de) 2003-02-26
US20090203615A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ATE283286T1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
ATE346160T1 (de) Proteingerüste für antikörper-mimetika und andere bindungsproteine
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DE69829293D1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
TW200611910A (en) Interferon-alpha polypeptides and conjugates
NO20030548D0 (no) Substratbehandling for rustfritt stål
IL167943A (en) Botulinum neurotoxin b receptors and use thereof
DE69739375D1 (de) Verfahren zur regulierung der stickstoffmonoxid-erzeugung
DE50111031D1 (de) Copolymermischungen und ihre Verwendung als Additiv zur Verbesserung der Kaltfliesseigenschaften von Mitteldestillaten
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
YU18903A (sh) Fuzioni proteini od inhibitora protivtela citokin- citokin (selektokin) kao ciljno specifični pro-lek
WO2002046228A3 (en) Receptor for b. anthracis toxin
DE60013093D1 (de) Methoden und kits zum sequenzieren von polypeptiden
TW200727909A (en) Enterokinesis promoting ingesta
ATE476447T1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
ATE319090T1 (de) Verwendung eines papillarfibroblast-spezifischen antikörpers als marker der hautqualität
ATE339683T1 (de) Verfahren zur detektion und konzentrationsbestimmung von schwefelfreien odoriermitteln in erd- oder brenngas
WO2003053855A3 (en) Rapid high-throughput screen for detecting biological species in ballast water
WO2005060998A3 (en) Methods of modulating cytokine activity; related reagents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition